Dicerna Pharmaceuticals Inc. started an underwritten public offering of its common stock.
Net proceeds will be used for preclinical studies and clinical trials, with the remainder being used for continued technology platform development, working capital and general corporate purposes.
Stifel and Evercore ISI are acting as the joint book-running managers for the offering. H.C. Wainwright & Co. and SunTrust Robinson Humphrey are acting as the co-lead managers for the offering.
